{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:01:21Z","timestamp":1790319681345,"version":"4.1.0"},"reference-count":96,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns. However, expansion in scientific knowledge of the mechanisms regulating appetite and energy balance has led to the development of medications with greater safety and efficacy. The current generation of injectable incretin analogs, semaglutide and tirzepatide, is associated with mean weight loss in the range of 15%\u201320% over approximately 12\u201318\u2009months. These agents confer additional substantial cardiometabolic benefits, including reductions in adverse cardiovascular and kidney outcomes, and improvements in glycaemia, blood pressure, lipid profile and steatohepatitis. As therapeutic options continue to expand, obesity medications are poised to play a critical role in the management of cardiometabolic disease.<\/jats:p>","DOI":"10.1002\/jgh3.70466","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:32:51Z","timestamp":1788579171000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolution of Medications for Obesity Management"],"prefix":"10.1002","volume":"10","author":[{"given":"Jaskirath","family":"Gill","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes Alfred Group, Bayside Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-1050","authenticated-orcid":false,"given":"Priya","family":"Sumithran","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Alfred Group, Bayside Health  Melbourne Australia"},{"name":"Department of Surgery, School of Translational Medicine Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"World Health Organization \u201cObesity and Overweight \u201d2025 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(11)60813\u20101"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000337\u20108"},{"key":"e_1_2_14_6_1","volume-title":"Endotext","author":"Bray G. A.","year":"2000"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010024\u201001530\u20106"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181\u2010011\u20100162\u20106"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.009621"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550\u20108528.1994.tb00061.x"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300655"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(97)11509\u20104"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200831010\u201000005"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/372425a0"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE\u201018\u20100596"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012\u20101272"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(11)60205\u20105"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.04.004"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2024.100472"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(10)60888\u20104"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801889"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003978\u2010z"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s1121"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(20)30364\u20108"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512275"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(19)30249\u20109"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.622589"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(25)00226\u20108"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010026\u201004386\u20107"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(26)00656\u20102"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010025\u201001859\u20106"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16601"},{"key":"e_1_2_14_49_1","unstructured":"Australian Diabetes Society \u201cClinical Practice Recommendations: Periprocedural Use of GLP\u20101RAs and GLP\u20101\/GIPRAs (April 2025) \u201d2026 https:\/\/www.diabetessociety.com.au\/guideline\/periprocedural\u2010use\u2010glp1ras\u2010and\u2010glp1\u2010gipras\u2010april\u20102025\/."},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.08.033"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2026.0027"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i581"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231205490"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14242829"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"e_1_2_14_56_1","unstructured":"GOV.UK \u201cGLP\u20101 Receptor Agonists and Dual GLP\u20101\/GIP Receptor Agonists: Strengthened Warnings on Acute Pancreatitis Including Necrotising and Fatal Cases \u201d2026 https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/glp\u20101\u2010receptor\u2010agonists\u2010and\u2010dual\u2010glp\u20101\u2010slash\u2010gip\u2010receptor\u2010agonists\u2010strengthened\u2010warnings\u2010on\u2010acute\u2010pancreatitis\u2010including\u2010necrotising\u2010and\u2010fatal\u2010cases."},{"key":"e_1_2_14_57_1","unstructured":"DailyMed \u201cMOUNJARO\u2010 Tirzepatide Injection Solution Mounjaro Kwikpen\u2010 Tirzepatide Injection Solution \u201d2026 https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d2d7da5d\u2010ad07\u20104228\u2010955f\u2010cf7e355c8cc0."},{"key":"e_1_2_14_58_1","unstructured":"DailyMed \u201cWEGOVY\u2010 Semaglutide Injection Solution WEGOVY\u2010 Semaglutide Tablet \u201d2026 https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ee06186f\u20102aa3\u20104990\u2010a760\u2010757579d8f77b."},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251406456"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103991"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100205"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00271\u20107"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)01375\u20103"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE\u201024\u20100259"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003015\u20105"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003327\u20106"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)00803\u2010X"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"e_1_2_14_75_1","unstructured":"Eli Lilly and Company \u201cA Master Protocol for a Randomized Controlled Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction\u2010Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes \u201dhttps:\/\/clinicaltrials.gov\/study\/NCT07165028."},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.08.029"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003018\u20102"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010026\u201004479\u20103"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_14_80_1","unstructured":"Boehringer Ingelheim \u201cA Randomised Double\u2010Blind Placebo\u2010Controlled Multicentre Phase III Trial Evaluating Long\u2010Term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non\u2010Alcoholic Steatohepatitis\/Metabolic Dysfunction\u2010Associated Steatohepatitis (NASH\/MASH) and (F2)\u2013(F3) Stage of Liver Fibrosis \u201d2026 https:\/\/clinicaltrials.gov\/study\/NCT06632444."},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695\u2010021\u201005394\u2010x"},{"key":"e_1_2_14_84_1","unstructured":"Eli Lilly and Company \u201cA Randomized Double\u2010Blind Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease \u201d2025 https:\/\/clinicaltrials.gov\/study\/NCT05882045."},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.11.009"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01751\u20107"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00356\u2010X"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600751"},{"key":"e_1_2_14_91_1","unstructured":"WHO \u201cIssues Global Guideline on the Use of GLP\u20101 Medicines in Treating Obesity \u201d2026 https:\/\/www.who.int\/news\/item\/01\u201012\u20102025\u2010who\u2010issues\u2010global\u2010guideline\u2010on\u2010the\u2010use\u2010of\u2010glp\u20101\u2010medicines\u2010in\u2010treating\u2010obesity."},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.6586"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.067676"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.2337\/db24\u20102066\u2010LB"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2025.2516522"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023"}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.70466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jgh3.70466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.70466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:54:34Z","timestamp":1790319274000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.70466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/jgh3.70466"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.70466","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"value":"2397-9070","type":"print"},{"value":"2397-9070","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70466"}}